Partner of choice: Why with us?
ROVI's profile and experience on the Spanish market make us an attractive licensee for the successful marketing of new products:
What we are looking for?
ROVI's activity is focused mainly in seven core franchises:
ROVI also has an OTC?Consumer Healthcare division.
ROVI presents a long history of strategic agreements supporting our experience and collaboration with biotechnological and pharmaceutical companies and public research centres. In this regard it is worth highlighting ROVI's commercial agreements with: Laboratoires Servier, Merck, Bracco, AstraZeneca, Sanofi Pasteur or Ebewe Pharma among others.
With the ultimate goal of maximizing the commercial potential of its internal R&D function, ROVI works actively with the granting of licences to third parties.
Bemiparin: Our international flagship molecule
The fruit of this policy and a successful case study is the internationalization of Bemiparin which is marketed in 52 countries out of Spain under agreements signed with licensees.
Currently, an important number of international pharmaceutical companies, have relied on our low molecular weight heparin, Bemiparin, product entirely developed by Laboratorios Farmacéuticos ROVI, S.A.
Last clinical trials with Bemiparin:
FOR MORE INFORMATION ABOUT BEMIPARIN:
Fibrilin: Our Class III medical device with CE marking
ROVI is nowadays actively working for the internationalization of Fibrilín®, our catheter lock solution for hospital use classified as Class III medical device with CE marking
FOR MORE INFORMATION ABOUT FIBRILIN VISIT:
Chondroitine Sulphate 400mg Rovi: Chondroprotector from Rovi for Knee Arthrosis.
ROVI is nowadays also actively searching for distribution partners for Chondroitin Sulpahte 400mg, which is now available for all the European countries.
If your company is interested in any of the ROVI´s business opportunities, please contact: